Simona Arcuti

Simona Arcuti

Auto-generated profile, based on publicly available information

Simona Arcuti

Unit of Neurodegenerative Diseases, department of Clinical Research in Neurology University of Bari "A. Moro" at Pia Fondazione Card. G. Panico Tricase, Lecce Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
GRGiovanni Rizzo
Giovanni Rizzo
MCMassimiliano Copetti
Massimiliano Copetti
SASimona Arcuti
Simona Arcuti
DMDavide Martino
Davide Martino
AFAndrea Fontana
Andrea Fontana
Giancarlo LogroscinoGiancarlo Logroscino
Giancarlo Logroscino
Objective: To evaluate the diagnostic accuracy of clinical diagnosis of Parkinson disease (PD) reported in the last 25 years by a systematic review and meta-analysis. Methods: We searched for articles published between 1988 and August 2014. Studies were included if reporting diagnostic parameters regarding clinical diagnosis of PD or crude data. The selected studies were subclassified based on different study setting, type of test diagnosis, and gold standard. Bayesian meta-analyses of available data were performed. Results: We selected 20 studies, including 11 using pathologic examination as gold standard. Considering only these 11 studies, the pooled diagnostic accuracy was 80.6% (95% credible interval [CrI] 75.2%–85.3%). Accuracy was 73.8% (95% CrI 67.8%–79.6%) for clinical diagnosis performed mainly by nonexperts. Accuracy of clinical diagnosis performed by movement disorders experts rose from 79.6% (95% CrI 46%–95.1%) of initial assessment to 83.9% (95% CrI 69.7%–92.6%) of refined diagnosis after follow-up. Using UK Parkinson's Disease Society Brain Bank Research Center criteria, the pooled diagnostic accuracy was 82.7% (95% CrI 62.6%–93%). Conclusion: The overall validity of clinical diagnosis of PD is not satisfying. The accuracy did not significantly improve in the last 25 years, particularly in the early stages of disease, where response to dopaminergic treatment is less defined and hallmarks of alternative diagnoses such as atypical parkinsonism may not have emerged. Misclassification rate should be considered to calculate the sample size both in observational studies and randomized controlled trials. Imaging and biomarkers are urgently needed to improve the accuracy of clinical diagnosis in vivo.

12 February 2016 in Neurodegenerative Diseases
Verified
Journal Article
Closed access
PDF file
BMBenoît Marin
Benoît Marin
SASimona Arcuti
Simona Arcuti
PJPierre Jesus
Pierre Jesus
GLGiancarlo Logroscino
Giancarlo Logroscino
MCMassimiliano Copetti
Massimiliano Copetti
O(On Behalf Of The French Register Of Als In Limousin (Fralim)
On Behalf Of The French Register Of Als In Limousin (Fralim)
Background/Aims: In a population-based setting, we aimed to (i) describe weight loss (WL) of amyotrophic lateral sclerosis (ALS) patients at the time of diagnosis and (ii) evaluate the association between WL and survival. Methods: All patients recruited in the FRALim register (2000-2013) were considered to be included in this study. Time-to-death analyses were performed using a multivariable Cox model. Model discrimination and calibration were assessed. Results: Among 322 patients in the register, 261 (81%) were included. At the time of diagnosis, 50.6% of patients reported a WL of more than 5%: 14.6% with WL between 5 and 10% and 36.0% with a WL of more than 10%. WL was independently associated with survival (p = 0.002). Patients with a WL of 10% or more experienced a 45% increase in the risk of death (95% CI 6-99) with respect to patients with a WL lower than 5% or no WL. The introduction of WL significantly improved the model's discrimination achieving a survival C statistic of 79.5% (95% CI 75.6-83.5, p = 0.006) at 12 months. Conclusion: More than 50% of ALS patients experience a WL of more than 5% at the time of diagnosis. This finding highlights the need for randomized trials to evaluate the effect of nutritional interventions to improve ALS survival.

30 October 2015 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
BMBenoît Marin
Benoît Marin
PCPhilippe Couratier
Philippe Couratier
SASimona Arcuti
Simona Arcuti
MCMassimiliano Copetti
Massimiliano Copetti
AFAndrea Fontana
Andrea Fontana
PPPierre Marie Preux
Pierre Marie Preux

28 January 2016 in International Psychogeriatrics
Verified
Journal Article
Closed access
PDF file
FVFederica Veneziani
Federica Veneziani
FPFrancesco Panza
Francesco Panza
VSVincenzo Solfrizzi
Vincenzo Solfrizzi
RCRosa Capozzo
Rosa Capozzo
MBMaria Rosaria Barulli
Maria Rosaria Barulli
GLGiancarlo Logroscino
Giancarlo Logroscino

25 March 2016 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RTR. Tortelli
R. Tortelli
MCM. Copetti
M. Copetti
FPFrancesco Panza
Francesco Panza
AFAndrea Fontana
Andrea Fontana
RCR. Cortese
R. Cortese
Giancarlo LogroscinoGiancarlo Logroscino
Giancarlo Logroscino

20 November 2015 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RTRosanna Tortelli
Rosanna Tortelli
MCMassimiliano Copetti
Massimiliano Copetti
SASimona Arcuti
Simona Arcuti
MTMarianna Tursi
Marianna Tursi
AIAnnalisa Iurillo
Annalisa Iurillo
Giancarlo LogroscinoGiancarlo Logroscino
Giancarlo Logroscino